Press release Communiqué de presse
Press release Communiqué de presse
September 3, 2013 3 September, 2013
Sernova to Present at 15th Annual Rodman & Renshaw Global Investment Conference
LONDON, ONTARIO (Marketwire -- Sept. 4, 2013) -
Sernova Corp. (TSX-V: SVA), today announced that Dr.
Philip Toleikis, Sernova's President and CEO, will present
at the 15th Annual Rodman & Renshaw Global Investment
Conference, sponsored by H.C. Wainwright & Co., LLC, at
12:30 p.m. EDT, Tuesday, Sept. 10, in room 7.03 at the
Millennium Broadway Hotel in New York City.
Dr. Toleikis will provide an overview of the company's business strategy and the ongoing Phase I/II clinical study of the Cell Pouch(TM) with insulin producing islets in patients with Type-1 diabetes.
If you are an institutional investor and interested in attending Sernova's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Dr. Toleikis.
About the Cell Pouch(TM)
The Cell Pouch(TM) is a proprietary scalable medical device which has been contract manufactured (ISO13485). It is placed under the skin, and forms an ideal environment rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type-1 diabetes receiving an islet transplant.
Sernova Corp is a clinical stage company developing medical technologies for the treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as hemophilia and other diseases to replace proteins or hormones in short supply in the body. Sernova is developing the Cell Pouch(TM), an implantable medical device which when placed under the skin forms an environment rich in tissue matrix and microvessels, ideal for placing therapeutic cells which then release proteins and/or hormones as required. The therapeutic cells are provided an immune-protected environment by Sernova's proprietary technology Sertolin(TM).
For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 firstname.lastname@example.org www.sernova.com
Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 email@example.com
Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.